Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Third Critically Ill Patient Successfully Treated with Pluristem's PLX Cells Under Compassionate Use

Published: Thursday, September 06, 2012
Last Updated: Thursday, September 06, 2012
Bookmark and Share
Patient with blood cancer, Acute Myeloid Leukemia, experienced improved clinical condition and released from Hadassah Hospital.

Pluristem Therapeutics, Inc. announced that the Company’s Placental eXpanded (PLX) cells were successfully administered to a third patient in Hadassah Medical Center; thus, a series of three life saving compassionate use treatments were completed. The outcome of those treatments potentially suggests that the Company’s PLX cells may have significant potential to treat a range of indications of bone marrow diseases.

The latest patient, a 45 year old male, diagnosed with Acute Myeloid Leukemia (AML), a form of blood cancer, underwent chemotherapy to treat the cancerous cells. Treatments with chemotherapy remove cancerous cells as well as normal cells in the bone marrow, leaving the patient needing bone marrow transplantation. The patient received an unrelated (allogeneic) bone marrow transplant. However, he suffered from severe and long standing pancytopenia with associated complications after receiving hematopoietic stem cell transplantations.
 
Due to the patient’s major life threatening condition, 144 days post bone marrow transplantation, PLX cells were injected intramuscularly (IM) at a dose of 600x106 cells, divided into two administrations, one week apart, under compassionate use treatment. No local or systemic side effects were observed. In addition, the patient’s general clinical condition and wellbeing significantly improved, resulting in his release from Hadassah Medical Center.
 
The series of the compassionate use treatments were led by Professor Reuven Or, Director of the Bone Marrow Transplantation and Cancer Immunology at Hadassah Medical Center in Jerusalem. Professor Or received a special permission by the Ministry of Health of the State of Israel, to try treating critically ill patients with bone marrow transplant failure that have no available alternative treatments, with PLX cells. According to Professor Or, “Following three successful treatments, which were conducted for the first time in the world, in Hadassah Medical Center, we can say that PLX cells from the placenta saved the life of patients suffering from bone marrow failure. We are very encouraged by the results and hope that future clinical trials will show the effectiveness of the PLX cells. I believe that the PLX treatment holds huge hope for patients who suffer from different conditions of bone marrow failure and once approved will be available for every patient who needs it.”
 
This is the third patient, out of three treated, to display impressive clinical improvement following the administration of PLX cells. The first two patients responded, four and nine days respectively, after the second PLX cell administration, with improvement of tri-linage hematopoiesis.
 
"We are extremely proud that the hard work, research and testing we have put into producing our PLX cells has now actively contributed towards saving the lives of these severely ill patients," said Zami Aberman, Chairman and CEO of Pluristem. "Additionally, with these three patients, we have data to suggest that our PLX cells may be helpful for rescuing both allogeneic as well as autologous bone marrow transplant failures."

Last month, Pluristem announced that it has filed the necessary documents requesting that the U.S. Food and Drug Administration (FDA) grant orphan drug status to its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia, a critical hematological emergency which is treated by a bone marrow transplantation. It has been estimated that there are 30,000 bone marrow transplants each year in the U.S. alone.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!